Exploring Three ASX Growth Companies With Significant Insider Ownership
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 27 2024
0mins
Source: Yahoo Finance
- Australian Market and Insider Ownership: Investors are monitoring the ASX amid macroeconomic concerns and fluctuating commodity prices, focusing on companies with high insider ownership for potential growth and resilience.
- Top 10 Growth Companies: Highlight of top Australian growth companies with high insider ownership, showcasing their earnings growth and insider ownership percentages.
- IperionX Company Overview: Details about IperionX, a company focused on mineral properties in the U.S., with insider ownership at 15.2% and revenue growth forecasted at 76.5% annually.
- Mesoblast Company Overview: Information on Mesoblast, operating in regenerative medicine products, with insider ownership at 22.2% and revenue growth forecasted at 55.3% per year.
- Technology One Company Overview: Insights into Technology One, a software solutions provider, with insider ownership at 12.3%, reporting revenue growth and net income increase, and an expected earnings growth rate of 14.22% annually.
Analyst Views on MESO
Wall Street analysts forecast MESO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MESO is 35.00 USD with a low forecast of 35.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 18.770
Low
35.00
Averages
35.00
High
35.00
Current: 18.770
Low
35.00
Averages
35.00
High
35.00
About MESO
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
